Navigation Links
Oncothyreon announces webcast of third quarter 2009 financial results conference call
Date:11/2/2009

SEATTLE, Nov. 2 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its third quarter 2009 financial results on Wednesday, November 11, 2009 after market close. Following the release, Oncothyreon's management expects to discuss these financial results and give a general business update in a conference call at 4:30 p.m. EST.

The discussion is planned for a live webcast and can be accessed at www.oncothyreon.com under the "News & Events" section. It is expected that the archive of the webcast will be available approximately one hour after completion of the discussion and will be posted on the Oncothyreon website for 30 days.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
2. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
3. Oncothyreon reports second quarter 2009 financial results
4. Oncothyreon announces closing of $15.0 million registered direct financing
5. Oncothyreon announces webcast of second quarter 2009 financial results conference call
6. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
7. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
8. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
9. Oncothyreon appoints Scott Peterson as Vice President of Research and Development
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Oncothyreon announces closing of $11.1 million registered direct financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) announced that, ... the size of the offering by 75% and purchase 3,684,212 ... to purchase 1,842,106 shares of common stock of the Company ... stock (the "Exercise Price"), at a price to the public ... The warrants have a term of four (4) years, exercisable ...
(Date:1/24/2017)... ... January 24, 2017 , ... Men who ... leptin levels had a positive association with increased prostate growth or benign prostatic ... International Neurourology Journal involved 571 Korean men who underwent urological examinations, including ...
(Date:1/24/2017)... Geneva, Switerland (PRWEB) , ... January 24, 2017 ... ... the first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of ... panels, which are available in a range of concentrations from six different malaria ...
(Date:1/24/2017)... 24, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) ... its orally active lead drug candidate, PBI-4050, has been ... UK Medicines and Healthcare Products Regulatory Agency ("MHRA") for ... A PIM designation is an early indication that a ... Access to Medicines Scheme ("EAMS"), intended for the treatment, ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
Breaking Biology News(10 mins):